Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2026-03-25 00:00:00 ET · period of report 2026-03-23 · accession 0001256153-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-25 | 2026-03-23 | OVID | LEVIN JEREMY M | Executive COB, Dir | M - OptEx | $1.40 | +47.3K | 3.74M | +1% | +$66.3K |
| D | 2026-03-25 | 2026-03-23 | OVID | LEVIN JEREMY M | Executive COB, Dir | M - OptEx | $0.00 | -47.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-23 | M | A | 47,333 | $1.40 | 3,735,048 | D | — | — | |
| 2 | Derivative | Series A Warrant (right to buy) | 2026-03-23 | M | D | 47,333 | $0.00 | 0 | D | $1.40 · — to 2026-04-17 | 47,333 Common Stock | (F2) Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025. |